



# OUTREACH SYMPOSIUM DRY EYE DISEASE

## 2 December 2021 | Livestream

Quinze-Vingts National Ophthalmology Hospital, Paris

### Keynote speakers

Virginia CALDER, PhD University College London

Margarita CALONGE, MD, PhD University of Valladolid and CIBER-BBN

IT-DED<sup>3</sup> beneficiaries



IT-DED<sup>3</sup> receives funding from the European Union's Horizon 2020 Research and Innovation Program under grant agreement No 765608

















#### **MORNING**

#### CHAIRED BY CHRISTOPHE BAUDOUIN, MD, PhD

President of the European Dry Eye Society - EuDES. Professor of Ophthalmology, chairman of department 3 of Ophthalmology in Quinze-Vingts National Ophthalmology Hospital



#### 08.45 - 08.50 OPENING & WELCOME NOTE BY THE CHAIRMAN

#### 08.50 - 09.00 INTRODUCTION TO IT-DED<sup>3</sup> NETWORK

Koen AUGUSTYNS, PhD, Coordinator of IT-DED<sup>3</sup>

Dean of the Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, Full Professor of Medicinal Chemistry, University of Antwerp



09.00 - 09.30 KEYNOTE LECTURE

#### T CELL SUBSETS IN OCULAR SURFACE INFLAMMATORY DISEASE

Virginia CALDER, PhD, Full professor of Ocular Immunology Ophthalmology Institute, University College London, IT-DED<sup>3</sup> External Advisory Board

09.30 - 10.00 BREAK



10.00 - 12.00 DRUG DISCOVERY

Presentations of 20 minutes followed by 10 minutes of Q&A and comments

Chaired by Amalia ENRIQUEZ-DE-SALAMANCA, PhD, Applied Ophthalmology Institute (IOBA), University of Valladolid.



10.00 - Alba RAMOS-LLORCA, University of Antwerp

Activity-based probes targeting serine proteases: a tool for biomarker identification



#### 10.30 - Camilla SCARPELLINI, University of Antwerp

Design, synthesis and biological evaluation of novel cell death inhibitors



Valorization of the olive by-products phenolic compounds and their evaluation as therapeutic agents for ocular surface inflammatory diseases



11.30 - Maha ABDALLAH, Institute of Experimental Biology and Technology - iBET

Extraction of bioactives using deep eutotic solvents from marine by-products for their potential application in the dry eye disease treatment





13.00 - 13.30 KEYNOTE LECTURE

#### THE SPECTRUM OF DRY EYE DISEASE - THERAPEUTIC IMPLICATIONS

Margarita CALONGE, MD, PhD, Full professor of Ophthalmology

Head of Ocular Surface Group at the Institute for Applied Ophthalmobiology (IOBA), University of Valladolid and CIBER-BBN

#### 13.30-16.00 PRECLINICAL DRUG DEVELOPMENT

Presentations of 20 minutes followed by 10 minutes of Q&A and comments

Chaired by Arto URTTI, PhD, Full professor, University of Eastern Finland.

13.30 - Agnese COMPAGNONE, University of Antwerp Implementation of in-vivo models to identify potential candidates for DED treatment

14.00 - Davide CERADINI, Latvian Insitute of Organic Synthesis

Upscaling of lead compounds from WPI and enantioselective synthesis of the serine protease inhibitor UAMC-00050


#### 14.30 - Luna KRSTIC, University of Valladolid

Development of new carriers to improve the bioavailability of topic formulations to treat ocular surface inflammatory diseases

15.00- Anusha BALLA, University of Eastern Finland Drug penetration to ocular surface tissues

15.30 - Bao TRAN GNOC, University Hospital Cologne

Dry eye therapy using cannabinoid ligands in a water-free delivery platform



#### 16.15 - 17.45 DEVELOPMENT OF CLINICAL DIAGNOSTIC TOOLS

Presentations of 20 minutes followed by 10 minutes of Q&A and comments

Chaired by Annabelle REAUX-LE-GOAZIGO, PhD, the Vision Institute

16.15 Murat Akkurt, Sorbonne University

Development of new biomarkers for Dry Eye Disease

16.45 Adrián Guerrero-Moreno, Sorbonne University

The nociceptive pathway in dry eye disease and ocular surface pain models

#### 17.15 Md Asif KHAN SETU, University Hospital Cologne

Development of novel diagnostic tools for dry-eye disease using infrared meibography, optical coherence tomography (OCT) and confocal microscopy



17.45 CLOSING WORDS

Serge PICAUD, PhD, Director of the Vision Institute



